Multiple halo naevi associated with tocilizumab

Autor:	M. Goodfield, K. Kuet
Rok vydání:	2014
Předmět:	Adult musculoskeletal diseases Angiogenesis medicine.medical_treatment Anti-Inflammatory Agents Arthritis Dermatology Vitiligo Antibodies Monoclonal Humanized chemistry.chemical_compound Tocilizumab medicine Humans skin and connective tissue diseases business.industry Interleukin medicine.disease Acquired immune system Cytokine chemistry Rheumatoid arthritis Immunology Female business Nevus Halo
Zdroj:	Clinical and Experimental Dermatology. 39:717-719
ISSN:	0307-6938
Popis:	Summary Tocilizumab, a humanized monoclonal antibody directed against the interleukin (IL)-6 receptor, is approved for the treatment of rheumatoid arthritis and juvenile idiopathic arthritis (JIA). We describe a case of multiple halo naevi occurring in a patient with a history of JIA treated with tocilizumab. IL-6 is a key cytokine in the setting of cancer through its effects on angiogenesis and inhibition of adaptive anti-tumour immunity. IL-6 also plays a role in melanocyte function, and increased levels have been noted in vitiligo skin, where it is a paracrine inhibitor of melanocytes. Tocilizumab may therefore lead to the development of halo naevi secondary to subsequent activation of adaptive immunity. Alternatively, as tocilizumab results in increased serum IL-6 levels, the epidermal cytokine profile is altered. Increased levels of IL-6 may therefore have a direct inhibitory effect on melanocytes, where access by tocilizumab may be limited due to differential size difference.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::53d66ba89566f6f6d6d1de5593ff1ec7 https://doi.org/10.1111/ced.12385 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.